Bliss GVS Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Bliss GVS Pharma's management has expressed confidence in the company's strategic growth initiatives, particularly its expansion into Sub-Saharan Africa and diversification of its product portfolio. These developments are crucial as they align with Vista's forecast of moderated revenue growth and ongoing margin pressures. The company's focus on scaling manufacturing capabilities, especially in semi-solid formulations, positions it to meet rising global demand, which supports Vista's outlook of a stable revenue trajectory despite current challenges. Additionally, the favorable macroeconomic environment in India, characterized by contained inflation and strong liquidity, enhances the company's operational landscape. However, potential headwinds such as regulatory challenges and pricing pressures in export markets warrant close monitoring. Over the next 12-24 months, key opportunities include leveraging geographical expansion and innovative product offerings, while watchpoints include currency fluctuations and geopolitical tensions that could impact supply chains. Overall, Bliss GVS Pharma is navigating a complex landscape, balancing growth opportunities with inherent risks, which Vista believes will lead to a cautious yet stable investment outlook
Why We Like This Stock
- Expansion into Sub-Saharan Africa enhances market reach and revenue potential
- Diversification of product offerings through innovation aligns with industry trends
- Strong manufacturing capabilities support increased global demand
Things To Watch Out For
- Ongoing margin pressures may impact profitability in the near term
- Regulatory challenges could hinder operational efficiency and market entry
- Currency fluctuations and geopolitical tensions pose risks to supply chains
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 770 | 810 | 927 | 1,110 | 1,202 |
| Profit Before Tax (Cr.) | 146 | 126 | 192 | 240 | 257 |
| PBT Margin | 19.0% | 15.6% | 2071.2% | 21.6% | 21.4% |
| Net Profit (Cr.) | 105 | 85 | 124 | 180 | 184 |
| Earnings Per Share | 9.4 | 7.5 | 11.2 | 16.2 | 17.4 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. The company offers anti-diabetic, anti-infective, anti-inflammatory, antifungal, antihemorrhoidal, antimalarial, antiseptic, cardiovascular, dermatological, gastrointestinal, gynaecology, neoro/cns, ophthalmic, otc drugs, respiratory, urology, and supplementary drug products, as well as engages in pain management services. It exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.